

肝炎文献リスト_2026年2月号

岡本宏明

2026-02-1

Epidemiology and control of widespread community hepatitis A outbreaks in 37 U.S. states, 2016-2023

Hofmeister M G, Yin S, Dokpesi P, Teshale E H, Eckert M, Gupta N

J Viral Hepat 33(2): e70137, 2026

PMID:41578878

米国37州でのA型肝炎アウトブレイク:流行状況と制御の実際(2016~2023年)

2026-02-2

Long-term protection from naturally acquired immunity against hepatitis E virus reinfection

Liu X, Zang X, Zhu K, Huang X, Hu X, Bi Z, Chen Q, Jiang H, Wang Y, Yang C, Liu D, Zhu W, Zheng Z, Su Y, Wu T, Huang S, Zhuang C, Zhang J, Xia N

Nat Commun 16:11187, 2025

PMID: 41407683

<https://doi.org/10.1038/s41467-025-66188-8>

自然感染で得られるHEV免疫の長期防御効果の検証

2026-02-3

Update on the molecular and cellular biology of hepatitis E virus and therapeutic opportunities

Corneillie L, Meziere L, Montpellier C, Drouet B, Aliouat-Denis C M, Cocquerel L

Antiviral Res 247:106353, 2026

PMID: 41571028

<https://doi.org/10.1016/j.antiviral.2026.106353>

HEVの分子細胞生物学の最新知見と治療への応用

2026-02-4

Structural mapping of NTCP distinguishes its dual functionality as a hepatitis B virus receptor and bile acid transporter

Matsuzawa K, Ekimoto T, Kobayashi C, Shionoya K, Mifune J, Morita T, Takeuchi J S, Park S Y, Ikeguchi M, Sureau C, Kawaguchi A, Watashi K

PLoS Pathog 22(1): e1013824, 2026

PMID: 41544142

<https://doi.org/10.1371/journal.ppat.1013824>

構造マッピングから明らかになったNTCPのHBV受容体機能と胆汁酸輸送機能の両立性

2026-02-5

Occult rat hepatitis E virus infection as a cause of cirrhosis and posttransplant recurrence: insights into the role of metagenomics

Fourgeaud J, Veyrenche N, Laloum I, Jais J P, Roger C, Rabant M, Mallet V, Beaufrere A, Fontaine H, Leruez-Ville M, Durand F, Anglicheau D

Am J Transplant 2026.01.005, Jan 10 [Epub ahead of print] PMID: 41525910

<https://doi.org/10.1016/j.ajt.2026.01.005>

原因不明の肝硬変の背景に潜むラットHEV感染:メタゲノム解析で見えた実態

2026-02-6

Beyond the liver: the broadened tissue tropism of hepatitis E virus

Schlienkamp S, Veiga O P, Kinast V, Steinmann E

Curr Opin Virol 74:101508, 2026

PMID: 41512736

<https://doi.org/10.1016/j.coviro.2025.101508>

HEV の多臓器感染性: 肝外病変の理解を深める

2026-02-7

Overview of gene editing strategies against HBV

Janetzki Z T, McCoullough L C, Revill P A, Littlejohn M

Antiviral Res 247:106355, 2026

PMID: 41571029

<https://doi.org/10.1016/j.antiviral.2026.106355>

HBV に対する遺伝子編集治療の最新戦略概要

2026-02-8

Evidence of rat hepatitis E virus circulation through wastewater surveillance, central Argentina

Filoni B, Lucero M E, Di Cola G, Fantilli A, Roccia A, Sicilia P, Luque L, Cachi A, de Los Angeles Marinzalda M, Castro G, Masachessi G, Re V, Pisano M B

Emerg Infect Dis 32(1):133-6, 2026

PMID: 41612580

<https://doi.org/10.3201/eid3201.251218>

アルゼンチン中部の下水調査で判明したラット HEV の流行

2026-02-9

Risk factors analysis for progression to severe hepatitis in acute hepatitis E: a retrospective study of 146 hospitalized cases

Chen J, Yin D, Zhou Y, Bai Y, Yan L, Yuan X, Wang J, Xu J, Bao Y

BMC Infect Dis 26:37, 2026

PMID: 41350819

<https://doi.org/10.1186/s12879-025-12233-2>

急性 E 型肝炎が重症化する危険因子: 入院 146 例の後ろ向き解析

2026-02-10

Single nucleotide polymorphisms in the bepirovirsin binding site have limited impact on treatment response in chronic hepatitis B

Bouquet J, Speer S D, Koenig A, Livingston C M, Savarese M, Lau C, Angelini E, Galwey N, Yates P, Maynard L, You S, Cremer J, Paff M, Theodore D, Elston R, Walker J

J Hepatol 2025.12.025, Jan 14 [Epub ahead of print]

PMID: 41544767

<https://doi.org/10.1016/j.jhep.2025.12.025>

ベピロビルセン結合部位の一塩基多型は慢性 B 型肝炎の治療効果に大きな影響を及ぼさない

2026-02-11

High-pressure processing of pork liver reduces the infectivity of the hepatitis E virus

Pellerin M, Martin J L, Harlet L, Doceul V, Pavio N, Feurer C

Appl Environ Microbiol e01054-25,

Dec 31 [Epub ahead of print] PMID: 41474335

<https://doi.org/10.1128/aem.01054-25>

豚レバーを高圧処理すると HEV の感染力は低下する

2026-02-12

HEV replication is promoted by blocking the NF- κ B signaling pathway through inhibiting FLNa expression

Xia Y, Chen S, He Q, Cong C, Long F, Wang Y, Liu H, Hu M, Hu X, Shen Y, Xu L, Li Y, Yu W, Wei D, Zhang C, Huang F

J Virol e01977-25, Jan 30 [Epub ahead of print]

PMID: 41615268

<https://doi.org/10.1128/jvi.01977-25>

FLNa 発現抑制を介した NF- κ B 経路の阻害が HEV 複製を促進する

2026-02-13

Identification of claudin-3 as an entry factor for rat hepacivirus

Tanaka T, Akaike Y, Kasai H, Yamashita A, Matsuura Y, Moriishi K

Proc Natl Acad Sci U S A 122(40): e2508736122, 2025

PMID: 41037638

<https://doi.org/10.1073/pnas.2508736122>

ラットヘパシウイルスの侵入因子として claudin-3 を同定

2026-02-14

Structural characterization of the HDV virion and its ribonucleoprotein

Itskanov S, Ary B, Mehra U, Lew I, Novikov N, Schmitz U, Holdorf M M, Beran R K, Lansdon E B

Proc Natl Acad Sci U S A 123(4): e2519809123, 2026

PMID: 41564123

<https://doi.org/10.1073/pnas.2519809123>

HDV 粒子およびリボヌクレオタンパク複合体の構造的特徴の解明

2026-02-15

Unveiling hepatitis E virus diversity in Sudan's internally displaced populations: a molecular epidemiology approach

Osman H A, Bakr W M K, Hashish M H, Elkhidir I M, Bedri S, Oyola S O, Norder H, Abd El-Wahab E W

Trop Med Health 53:186, 2025

PMID: 41387920

<https://doi.org/10.1186/s41182-025-00864-9>

スーダン国内避難民における HEV 多様性の解明: 分子疫学的アプローチ

2026-02-16

Seroprevalence of hepatitis E in general, hepatic, and pregnant populations in Nepal, Bangladesh, and Pakistan: a systematic review and meta-analysis

Gupta B P, Sah A K, Sah A K, Gupta V P, Ghimire D P, Acharya N, Wagle C

Viol J 23:6, 2026

PMID: 41350906

<https://doi.org/10.1186/s12985-025-03027-8>

南アジア3か国(ネパール、バングラデシュ、パキスタン)における一般住民・肝疾患患者・妊婦における HEV 抗体陽性率: 系統的レビューとメタ分析

2026-02-17

Expanding the spectrum of chronic hepatitis E in kidney transplantation: first report of HEV-3ra infection and review of literature

Matias E F, Azevedo M, Sampaio S, Pinho A T, Conde S, Rebelo S, Santos-Silva S, Nascimento M S J, Mesquita J R, Santos L

Front Med (Lausanne) 12:1705331, 2025

PMID: 41438147

<https://doi.org/10.3389/fmed.2025.1705331>

腎移植後の慢性 E 型肝炎の新たな側面: ウサギ HEV (HEV-3ra)感染の初報と文献レビュー

2026-02-18

Shellfish as a potential source of hepatitis E virus: Epidemiological evidence, biological plausibility, and research gaps

Okamoto H

Viruses 18(2):220, 2026

<https://doi.org/10.3390/v18020220>

貝類は HEV の感染源となり得るのか: 疫学的証拠、生物学的妥当性、そして残された課題

2026-02-19

Exacerbation of anti-cytomegalovirus immunity and mobilization of $\gamma 9 \delta 1$ T cells during the acute phase of hepatitis E virus infection

Retailleau M, Martini F, Abravanel F, Kamar N, Izopet J, Champagne E

Microbiol Immunol 70034, Dec 15 [Epub ahead of print]

PMID: 41395767

<https://doi.org/10.1111/1348-0421.70034>

急性 HEV 感染に伴う抗 CMV 免疫反応の増強と $\gamma 9 \delta 1$ T 細胞の動員

2026-02-20

Glucose-6-phosphate dehydrogenase deficiency facilitates hepatitis E virus entry and aggravates liver injury

Chen D, Hu X, Xue Y, Xia F, Li M, Liu J, Huang F

Viol J 025-03031-y, Dec 17 [Epub ahead of print]

PMID: 41408562

<https://doi.org/10.1186/s12985-025-03031-y>

G6PD 欠損症は HEV の侵入を促進し、肝障害を悪化させる

2026-02-21

Hepatitis A to E in people with HIV: A virus-specific review of prevention and treatment
Lin K Y, Huang Y C, Huang M H, Tsai T Y, Chen G J, Huang Y S, Huang S H, Sun H Y, Hung C C

Infect Dis Ther 025-01282-4, Dec 18 [Epub ahead of print] PMID: 41408032

<https://doi.org/10.1007/s40121-025-01282-4>

HIV 感染者における A 型～E 型肝炎: ウイルス別の予防と治療レビュー

2026-02-22

Burden of rodent-borne viruses in rodents and zoonotic risk in humans in Cambodia

Guillebaud J, Nouhin J, Hul V, Hoem T, Yanneth O, Sim M, Khun L, Y P, Heng L, Ken S, Pum L, Lim R, Meng C, Chhel K, Nuon S, Hoem S, Nguon K, Chan M, Ly S, Karlsson E A, Reynes J M, Sakunthabhai A, Dussart P, Duong V

Microbiol Spectr 14(1): e01394-25, 2026

PMID: 41496158

<https://doi.org/10.1128/spectrum.01394-25>

カンボジアの野生齧歯類に見られるウイルス感染と人獣感染の危険性

2026-02-23

Acute hepatitis E virus infection as a trigger for postinfectious IgA nephropathy: A rare case report

Khan M, Khan Z, Altaf A, Bibi S, Batool I, Naamani A E R, Fakhri N

Medicine (Baltimore) 104(52): e46341, 2025

PMID: 41466005

<https://doi.org/10.1097/MD.00000000000046341>

急性 HEV 感染が引き金となった IgA 腎症の1例

2026-02-24

Hepatitis E virus in pigs at the moment of slaughter in Spain, 2015 and 2017

Garcia N, Hernandez M, Santamaria-Palacios J, Martinez I, Navarro A, Munoz-Chimeno M, Escobar F, Fongaro G, Yeramian N, Trzaskowska M, Avellon A, Eiros J M, Dominguez L, Valero A, Goyache J, Rodriguez-Lazaro D

Food Microbiol 136:105011, 2026

PMID: 41478688

<https://doi.org/10.1016/j.fm.2025.105011>

スペインにおける屠殺時の豚での HEV 陽性率(2015・2017 年)

2026-02-25

Low HBV replication does not aggravate disease progression in patients with superinfection with HEV

Chen L, Dai S, Wu J, Gao X, Liu X, Shao Y

Sci Rep 025-34028-w, Dec 27 [Epub ahead of print]

PMID: 41454152

<https://doi.org/10.1038/s41598-025-34028-w>

HBV が低いレベルで増える場合、HEV の重複感染でも病状は悪化しない

2026-02-26

Meta-analysis of global prevalence of hepatitis E virus infection in deer

Gao Z Q, Bao G R, Wang H T, Wei Y J, Zhang M, Tan W X, Liu H L, Zhao Q, Gong Q L, Jiang J, Qin Y

Front Microbiol 16:1741279, 2025

PMID: 41488300

<https://doi.org//10.3389/fmicb.2025.1741279>

世界のシカにおける HEV 感染率の推定:メタ解析

2026-02-27

Trends and projections of hepatitis E incidence in Jiangsu Province of eastern China from 2007 to 2021: An analysis based on age-period-cohort models

Cheng X, Zhang Z, Kang W, Zhang X, Peng H, Bao C

Infect Dis Model 10(4):1093-102, 2025

PMID: 40547860

<https://doi.org/10.1016/j.idm.2025.05.011>

2007~2021年の中国江蘇省のE型肝炎発生状況と将来予測:年齢・時期・世代別の解析

2026-02-28

Effect of direct-acting antivirals on prognosis in older patients with hepatitis C virus-related hepatocellular carcinoma after curative therapy: A retrospective study by the Red Cross Liver Study Group in Japan

Ochi H, Kurosaki M, Tanaka T, Akahane T, Marusawa H, Kobashi H, Fujii H, Morita A, Uchida Y, Okada K, Urawa N, Mori N, Tsuji K, Okamoto E, Ogawa C, Kondo M, Nonogi M, Uchino K, Yoshida H, Izumi N

Hepatol Res 70122, Jan 11 [Epub ahead of print]

PMID:41521590

治癒後の高齢HCV関連肝癌患者におけるDAA治療の予後改善効果:日赤肝臓研究グループによる後ろ向き研究

2026-02-29

Long-term post-transplant outcomes in patients with hepatitis D virus infection at a high-volume liver transplant center

Keser M F, Keser Z B, Yurdaydin C, Yilmaz S, Harputluoglu M

Dig Dis Sci 025-09654-z, Jan 6 [Epub ahead of print]

PMID: 41495386

<https://doi.org/10.1007/s10620-025-09654-z>

HDV感染患者の肝移植後の長期予後:大規模移植センターのデータ

2026-02-30

Clinical characteristics of indeterminate chronic hepatitis B patients with and without liver biopsy

Xiong Y, Wang J, Song Y, Fan T, Zhu L, Zhang S, Jiang C, Liu J, Yin S, Tong X, Xia J, Yan X, Chen Y, Shi Y, Qiu Y, Zhu C, Liu X, Wu C, Huang R

Hepatol Res 70094, Dec 13 [Epub ahead of print]

PMID:41389326

不確定期(グレーゾーン)慢性B型肝炎における臨床的特徴:肝生検判断に対する非侵襲的線維化指標の診断的意義

2026-02-31

High hepatitis E virus prevalence in pig slurry samples from the north-western region of Germany

Hinte F, Lutgehetmann M, Meister T L, Giersch K, Dandri M, Wiesch J S Z, Pischke S
One Health 22:101291, 2026 PMID: 41480311

<https://doi.org/10.1016/j.onehlt.2025.101291>

豚糞尿サンプルからの HEV 高検出率:ドイツ北西部の調査

2026-02-32

Functional annotation of HBV-associated host genetic variants in the Saudi population: A bioinformatic analysis for precision hepatitis B research

Khalid S S, Alswat K
Infect Genet Evol 138:105878, 2026 PMID: 41564913

<https://doi.org/10.1016/j.meegid.2026.105878>

サウジアラビア人における HBV 関連宿主遺伝子変異の機能解析: 精密医療に向けたバイオインフォマティクス研究

2026-02-33

Chronic hepatitis B infection: Patient guidance

Mak L Y, Lai J C, Liu K, Lui R, Chirapongsathorn S, Yew K C, Panlilio M T, Lesmana C R A, Rajaram R B, Shen L, Cheung D, Wong L F, Lee H W, Premkumar M, Kulkarni A V, Tamaki N, Hsu Y C, Huang D Q
J Gastroenterol Hepatol 41(1):61-77, 2026 PMID: 41360731

<https://doi.org/10.1111/jgh.70177>

慢性 B 型肝炎: 患者向けガイド

2026-02-34

Predictive value of serum Mac-2 binding protein glycosylation isomer for hepatic fibrosis in hepatitis C virus-infected patients with metabolic dysfunction-associated steatotic liver disease

Chen Y C, Chang Y P, Lee J Y, Chen C Y, Kao W Y, Lin C L, Yang S S, Shih Y L, Peng C Y, Lee F J, Tsai M C, Huang S C, Su T H, Tseng T C, Liu C J, Chen P J, Kao J H, Liu C H
J Gastroenterol Hepatol 41(1):322-31, 2026 PMID:41236046

MASLD を伴う HCV 感染例における M2BPGi の肝線維化予測能

2026-02-35

Immune checkpoint inhibitor-induced rapid decline in HBV markers improves the prognosis of HBV-related hepatocellular carcinoma patients

Ran Y, Zhu M, Wang K, Xia Y, Zhu Y, Zang M, Kang S, Li Q, Hu X, Wang Y, Liu F, Chen X, Zhao Q, Liu H, Liu D, Chen H, Chen J, Guo Y, Fan R
J Infect Dis jiag036, Jan 16 [Epub ahead of print] PMID: 41540638

<https://doi.org/10.1093/infdis/jiag036>

免疫チェックポイント阻害剤による HBV マーカーの急速な減少は、HBV 関連肝癌患者の予後改善の指標である

2026-02-36

SOX6 is a novel host factor that promotes hepatitis B virus replication by enhancing the transcriptional activity of enhancer I

Song Y, Zeng Y, Zheng H, Shi S, Li Z, Liu M, Shao S, Luo Z, Li Y, Li J, Xiang K, Wang J
Antiviral Res 247:106359, 2026 PMID: 41616818

SOX6 はエンハンサーIの活性化を通じてHBV複製を促進する新規宿主因子である

2026-02-37

Estimated hepatitis C prevalence and viral clearance using residual sera from a large commercial laboratory - November 2023-September 2024

Hofmeister M G, Symum H, Swanson B E, Barker L K, Zhong Y, Kaufman H W, Thompson W W, Meyer W A, 3rd, Gupta N

Clin Infect Dis ciag007, Jan 8 [Epub ahead of print] PMID: 41502122

米国の大手検査会社の残余血清からみたC型肝炎の流行状況とウイルス排除の推定(2023年11月~2024年9月)

2026-02-38

Hepatitis B outcomes after switching to long-acting cabotegravir/rilpivirine in people with HIV: Reactivation, incident infection, and liver safety across diverse serological profiles

Foncillas A, Ambrosioni J, Sempere A, Berrocal L, Calvo J, Chivite I, de la Mora L, Inciarte A, Torres B, Martinez-Rebollar M, Blanco J L, Miro J M, de Lazzari E, Martinez E, Mallolas J, Gonzalez-Cordon A, Laguno M

Clin Infect Dis ciag023, Jan 14 [Epub ahead of print] PMID: 41539988

<https://doi.org/10.1093/cid/ciag023>

HIV患者でカボテグラビル/リルピビルンへの切り替え後のHBVの再活性化・新規感染・肝安全性の検討

2026-02-39

Evaluation of fingerstick blood point-of-care testing of hepatitis B DNA for enhanced hepatitis B treatment decision making: a diagnostic accuracy study

Hajarizadeh B, George J, Levy M T, Wong I, Howell J, Cabrera G, Tu E, Martinello M, Applegate T L, Matthews G V

J Clin Microbiol e01405-25, Jan 20 [Epub ahead of print] PMID: 41556653

<https://doi.org/10.1128/jcm.01405-25>

指先採血によるHBV DNA迅速検査の有用性: 治療判断を支える精度評価

2026-02-40

GLS4 induces the interferon signaling pathway during hepatitis B virus (HBV) infection

Zhao L, Xu S, Yao S, Wei Z, Lou G, Qi J, Xu H, Wang X, Yang Z, Zheng M

J Med Virol 98(1): e70777, 2026 PMID:41480806

GLS4はHBV感染時にIFNシグナルを誘導する

2026-02-41

Comparative performance of the Siemens Atellica and Abbott Architect assays for HBsAg quantification in patients with chronic hepatitis B or hepatitis Delta

Badot L, Hilleret M N, Guergour D, Chirica C, Truffot A, Morand P, Germi R, Scholtes C, Larrat S, Lupo J

J Clin Virol 182:105913, 2026

PMID: 41547246

<https://doi.org/10.1016/j.jcv.2026.105913>

慢性 B 型肝炎および HDV 患者における HBsAg 測定: シーメンス Atellica と アボット Architect の性能評価

2026-02-42

Performance of Elecsys Anti-HEV IgG and IgM assays for the detection of acute, recent or past hepatitis E virus infection

Schemmerer M, Pfluger L S, Schneider T, Lu J, Kienle K, Meyer-Schlinkmann K M, Muhlbacher A, Polz J, Schennach H, Xie Q, Voitenleitner C, Wenzel J, Lutgehetmann M

Liver Int 46(1): e70480, 2026

PMID: 41395844

<https://doi.org/10.1111/liv.70480>

Elecsys 抗 HEV IgG/IgM アッセイの性能評価: 急性・最近・既感染の判定精度

2026-02-43

Analysis of hepatitis B virus integration reveals new insights of oncogenic mechanism in dysplastic liver nodule

Zeng X, Liu H, Xu Z, Rao X, Wang Y, Peng F, Dong W, Wang Z, Wang Z, Gu X, Liu F, Li G, Zhou W, Zhao L

J Med Virol 98(1): e70755, 2026

PMID:41499541

HBV 組み込み解析から明らかになった異形成肝結節における発癌メカニズムの新知見

2026-02-44

Dynamics of serum hepatitis B virus nucleic acids in patients with chronic hepatitis B after stopping nucleos(t)ide analogs reveal delayed rebound of hepatitis B virus RNA

Li W, Deng R, Fan R, Liang X, Lu X, Liang H, Liang W, Zeng G, Chen Y, Hou J, Sun J, Shen S, Liu S

J Med Virol 98(1): e70764, 2026

PMID:41439722

慢性 B 型肝炎患者における核酸アナログ中止後の血中 HBV 核酸動態: HBV RNA の遅延リバウンドが判明

2026-02-45

Effect of glycated hemoglobin levels on serum Mac-2 binding protein glycosylation isomer in the diagnosis of hepatitis C-virus related hepatic fibrosis

Chang Y P, Chen Y C, Lee J Y, Chen C Y, Kao W Y, Lin C L, Yang S S, Shih Y L, Peng C Y, Lee F J, Tsai M C, Huang S C, Su T H, Tseng T C, Liu C J, Chen P J, Kao J H, Liu C H

J Med Virol 98(1): e70797, 2026

PMID:41536202

HCV 関連肝線維化評価における M2BPGi の精度に糖化 Hb 値が及ぼす影響

2026-02-46

A machine learning model for predicting complete virological response in chronic hepatitis B patients receiving first-line nucleos(t)ide analogues therapy

Yuan X, Xiang X, Xu H, Lu W, Zhang J, Hu Z, Li S, Zhou L

J Clin Virol 183:105921, 2026

[第一選択核酸アナログ治療中の慢性 B 型肝炎患者におけるウイルス抑制予測モデル\(機械学習\)](#)

2026-02-47

Hepatitis B vaccination uptake and associated factors in the United States before implementing universal vaccination: A nationally-representative study

Cater M G, Olasehinde T, Kim A, Choudhary E, Yendewa G A

J Viral Hepat 33(1): e70125, 2026

PMID:41432076

[米国における B 型肝炎ワクチン接種率と関連因子:ユニバーサル接種導入前の全国調査](#)

2026-02-48

Prevalence of hepatitis B among migrants living in high-income countries with low/intermediate HBV prevalence - a systematic review and meta-analysis

Sun J, Pourmarzi D

J Viral Hepat 33(2): e70106, 2026

PMID:41562241

[高所得国に移住した移民における HBV 有病率:系統的レビューとメタ解析](#)

2026-02-49

Characteristics of newly reported chronic hepatitis C cases among adults in the United States, 2016-2023: Insights from population-based surveillance

Yin S, Hofmeister M G, Thompson N D, Teshale E H

J Viral Hepat 33(2): e70123, 2026

PMID:41482805

[米国成人における新規慢性 C 型肝炎報告例の特徴\(2016~2023 年\)](#)

2026-02-50

Association between indirect bilirubin percentage to albumin ratio and outcome of hepatitis B related acute on chronic liver failure treated with artificial liver support system

Tang W, Ma Y, Du L, Bai L, Tang H

J Viral Hepat 33(2): e70131, 2026

PMID:41510593

[HBV 関連 ACLF における間接ビリルビン/アルブミン比と予後:人工肝補助システム施行例での検討](#)

2026-02-51

Evaluation of dried blood spot testing for serological monitoring of epizootic and zoonotic pathogens in domestic pigs

Steinhauer R, Kubler E, Gaugler S, Fraefel C, Lechmann J

J Virol Methods 341:115336, 2026

PMID: 41448255

<https://doi.org/10.1016/j.jviromet.2025.115336>

[豚における流行性・人獣共通感染症の血清学的モニタリングに対する乾燥血液スポット法の評価](#)

2026-02-52

Epigenetic mechanisms involved in HCV infection and human HCC

Lopes X, Silva Junior R R D, Fernandes F L, de Oliveira L A C, Andrade V S, Bezerra F L, de Araujo J M G, de Azevedo J C V, Fernandes T, Fernandes J V

Int J Mol Sci 26(24):12045, 2025

PMID: 41465470

<https://doi.org/10.3390/ijms262412045>

HCV 感染と HCC に関するエピジェネティック機構

2026-02-53

Advances in novel detection technologies for occult hepatitis B virus infection: Building an ultra-sensitive barrier for transfusion safety

Yi M, Hu Y, Fan B, Pan Y, Pan B, Wang J, Liu Z

Microorganisms 13(12):2821, 2025

PMID: 41472024

<https://doi.org/10.3390/microorganisms13122821>

Occult HBV 感染(OBI)を見逃さないための新規超高感度 HBV 検査法の最新動向

2026-02-54

Genetic characterization of hepatitis C virus among people who use crack cocaine: A study conducted on the Brazilian Amazon coast

Heymbeeck J A A, do Nascimento W L, Freitas M C S, de Sousa Rocha L, Costa F F, de Queiroz J P Q, Simeone D, Martins L C, Machado L F A, Fischer B, Kupek E, Oliveira-Filho A B

Pathogens 14(12):1296, 2025

PMID: 41471251

<https://doi.org/10.3390/pathogens14121296>

ブラジル・アマゾン沿岸地域のクラックコカイン使用者における HCV 遺伝子型の特徴

2026-02-55

A replication-competent deltavirus from the marsupial fat-tailed dunnart *Sminthopsis crassicaudata*

Denis Z, Courgnaud V, de la Pena M, Majzoub K

J Gen Virol 107(1):002203, 2026

PMID: 41543882

<https://doi.org/10.1099/jgv.0.002203>

フクロネズミ(ファットテール・ダンナート)から検出された複製可能デルタウイルスの報告

2026-02-56

A single-cell atlas of the woodchuck liver reveals cellular programs conserved in human HBV infection

Clarke Z A, Atif J, Wang X, Liu L Y, Wood L, Camat D, Liu Y, Shiwram A, Hyduk S J, Chung S, Ma X Z, Manuel J, Lok S, Lau T N H, Thoeni C, Michalak T I, McGilvray I D, Bader G D, MacParland S A

J Hepatol 2025.12.030, Jan 22 [Epub ahead of print]

PMID:41580091

ウッドチャック肝臓の単一細胞解析から見えた、ヒト HBV 感染と共通する細胞プログラム

2026-02-57

Mechanistic study of miR-148a-3p-mediated AMPK/mTOR/S6-dependent autophagy in hepatitis B virus replication

Liu J, Sheng Y

Virus Genes 025-02201-y, Jan 5 [Epub ahead of print] PMID:41491342

[miR-148a-3p が誘導する AMPK/mTOR/S6 経路を介したオートファジーと HBV 複製の関係](#)

2026-02-58

Genetic diversity of the hepatitis C virus among patients with HIV in EECA countries

Ekushov V E, Halikov M R, Osipova I P, Totmenin A V, Gotfrid L G, Arzakanyan V G, Martoyan S V, Lalayan K V, Hovsepyan T V, Petrosyan L H, Muradyan S G, Hovakimyan H M, Bekbolotov A A, Narmatova E B, Karagulova A S, Momushova K T, Djusupbekova A K, Iskanova B M, Mamirbaeva A K, Motorov U T, Minikhanova V V, Skudarnov S E, Ostapova T S, Agafonov A P, Gashnikova N M

Viruses 18(1):16, 2026

PMID: 41600780

<https://doi.org/10.3390/v18010016>

[東欧・中央アジア地域の HIV 患者での HCV 遺伝子型分布と多様性](#)

2026-02-59

Key challenges in screening blood donors for hepatitis B virus

Badawi M A, Eldakhakhny S, Ali M, Badawi M, Khiariy J, Bin-Taleb Y, Hindawi S I

Viruses 18(1):23, 2026

PMID: 41600789

<https://doi.org/10.3390/v18010023>

[HBV の献血者スクリーニングにおける主要な課題](#)

2026-02-60

Extended duration of anti-HEV IgM seropositivity in asymptomatic blood donors: Implications for transfusion safety

Kempski J, Mader M, Huber S, Peine S, Hiller J, Schulze Zur Wiesch J, Pischke S

Viruses 18(1):88, 2026

PMID: 41600852

<https://doi.org/10.3390/v18010088>

[無症候献血者での抗 HEV-IgM 抗体長期陽性化: 輸血安全性への示唆](#)

2026-02-61

Seroprevalence of hepatitis A virus (HAV) and hepatitis E virus (HEV) among blood donor candidates in Salvador, Bahia, Brazil

Mendes D S, Parana V C, Santos L H P, Cavalcanti L A d S, Alves J S F, Novais F S, de Souza Benicio dos Santos G, Matos H R S S d, Santana N P, Zarife M A S A, Santos C C d, Couto R D, Schinoni M I, Lyra A C, Reis M G d, Silva L K

Viruses 18(2):162, 2026

<https://doi.org/doi:10.3390/v18020162>

[ブラジルの献血志願者における HAV および HEV の抗体陽性率](#)

2026-02-62

Full-genome hepatitis B virus genotyping: A juxtaposition of next-generation and clone-based sequencing approaches - comparing genotyping methods of hepatitis B virus

Hu L P, Chen Q Y, Huang M L, Zhang W J, Huang X Q, Yi X F, Jia H H

Viruses 18(1):112, 2026

PMID: 41600874

<https://doi.org/10.3390/v18010112>

HBV の全ゲノム遺伝子型解析における次世代シーケンシング法と従来法の比較

2026-02-63

Direct viral mechanisms underlying the onset of HBV-related hepatocellular carcinoma and implications for therapeutic strategies

La Frazia S, Magnapera A, Piermatteo L, D' Anna S, Duca L, Svicher V, Salpini R

Viruses 18(2):185, 2026

<https://doi.org/10.3390/v18020185>

HBV 関連肝細胞癌発症の基盤となる直接的なウイルスメカニズムと治療戦略への示唆

2026-02-64

Development of a sensitive and specific RPA-CRISPR/Cas12a assay for intrahepatic quantification of HBV cccDNA

Kongsomboonchoke P, Ariyachet C, Kaewsapsak P, Sirichindakul P, Tangkijvanich P

Int J Mol Sci 27(1):551, 2026

PMID: 41516423

<https://doi.org/10.3390/ijms27010551>

HBV cccDNA の肝内定量のための高感度かつ特異的な RPA-CRISPR/Cas12a アッセイの開発

2026-02-65

Targeted removal of HCV E2 N2 N-glycan is associated with improved immune responses in mice

Min Y-Q, Ren Y-S, Zhang W-W, Zhou Y-D, Liu M

Biomolecules 16(2):183, 2026

<https://doi.org/10.3390/biom16020183>

HCV のエンベロープ糖たんぱく質(E2)の N2 部位での N 型糖鎖を特異的に除去すると、マウスにおける免疫応答が改善する

2026-02-66

Association between SGLT2 inhibitor use and reduced risk of liver-related events, including hepatocellular carcinoma, in diabetic patients with viral hepatitis: A nationwide cohort study

Kang S H, Choi J, Yim H J, Jung Y K, Yim S Y, Lee Y S, Seo Y S, Kim J H, Yeon J E, Byun K S

Cancers (Basel) 18(1):120, 2026

PMID: 41514629

<https://doi.org/10.3390/cancers18010120>

SGLT2 阻害薬はウイルス性肝炎合併糖尿病患者の肝関連イベント(HCC を含む)を減少させる: 全国規模コホート研究

2026-02-67

Unveiling the hidden reservoir: High prevalence of occult hepatitis B and associated surface gene mutations in a healthy Vietnamese adult cohort

Thu H H K, Ostankova Y V, Shchemelev A N, Serikova E N, Davydenko V S, Ton T, Lien T T X, Ramsay E S, Totolian A A

Microorganisms 14(1):238, 2026

PMID: 41597756

<https://doi.org/10.3390/microorganisms14010238>

健康ベトナム成人に occult HBV 感染が高頻度に存在: HBsAg 変異の特徴

2026-02-68

Triterpenoids CDDO and CDDO-EA inhibit the replication of hepatitis B virus by modulating nucleocapsid assembly

Gao Q, Yang G, Wang Y, Yang L, Hu J, Wang H, Yan H, Wang K, Wu S, Li Y, Jiang J

Int J Mol Sci 27(1):300, 2026

PMID: 41516181

<https://doi.org/10.3390/ijms27010300>

トリテルペノイド(CDDO と CDDO-EA)は、ヌクレオカプシドの組み立てを調節することで HBV の複製を抑制する

2026-02-69

The role of Aurora kinase A in HBV-associated hepatocellular carcinomas: A molecular and immunohistochemical study

Huz M, Karadag Soylu N, Koc A, Kucukakcali Z, Danis N, Ozhan O

Diagnostics (Basel) 16(1):160, 2026

PMID: 41515655

<https://doi.org/10.3390/diagnostics16010160>

HBV 関連肝細胞癌におけるオーロラキナーゼ A の役割: 分子生物学的・免疫組織化学的検討

2026-02-70

Assessment of liver fibrosis stage and cirrhosis regression after long-term follow-up following sustained virological response

Canillas L, Naranjo D, Broquetas T, Sanchez J, Pocurull A, Garrido E, Fernandez R, Forn X, Carrion J A

Diagnostics (Basel) 16(2):279, 2026

PMID: 41594255

<https://doi.org/10.3390/diagnostics16020279>

C 型肝炎 SVR 後の肝線維化ステージ評価と肝硬変改善の実態調査

2026-02-71

Hepatitis E ORF2 blocks trophoblast autophagy to induce miscarriage via LC3B binding rather than PI3K/Akt/mTOR pathway suppression

Chen Y, Yang Y, Bai Q, Tian X, Zhou C, Lu X, Liu T

Microorganisms 14(1):181, 2026

PMID: 41597697

<https://doi.org/10.3390/microorganisms14010181>

HEV ORF2 は LC3B 結合による栄養膜細胞オートファジー阻害を介して流産を誘発する (PI3K/Akt/mTOR 非依存)

2026-02-72

Hepatic macrophages in chronic hepatitis B: Balancing immunity and pathology

Pathania A S, Bhat S A, Adepoju L A, Kharbanda K K, Osna N A

Biology (Basel) 15(1):76, 2026

PMID: 41514917

<https://doi.org/10.3390/biology15010076>

慢性 B 型肝炎における肝マクロファージの役割: 免疫と病態のバランス

2026-02-73

Association of p53 Pro72Arg polymorphism with hepatocellular carcinoma risk in hepatitis B across multiethnic populations

Kholili U, Hidayat A A, Bintoro U Y, Soetjipto S, Aryati A, Alaydrus A, Miftahussurur M

Cancers (Basel) 18(3):380, 2026 <https://doi.org/10.3390/cancers18030380>

p53 Pro72Arg 多型と HBV 関連肝癌リスク: 多民族集団での検討

2026-02-74

Onnamides A and B suppress hepatitis B virus transcription by inhibiting viral promoter activity

Hayashi Y, Arizono S, Higa N, Tyas T A, Akahori Y, Maeda K, Toyama M, Mori-Yasumoto K, Yasumoto-Hirose M, Miyakawa K, Tanaka J, Jomori T

Mar Drugs 24(1):21, 2026

PMID: 41590717

<https://doi.org/10.3390/md24010021>

オンナミド A/B は、HBV プロモーター活性を阻害しウイルス転写を抑制する

2026-02-75

Retreatment of direct acting agents (DAAs) after initial DAA failure in hepatitis C patients

Tamaki N, Kurosaki M, Ochi H, Fujii H, Suzuki Y, Sho T, Hikita H, Marusawa H, Asahina Y, Izumi N, Kanto T

Hepatol Res 70128, Jan 29 [Epub ahead of print]

PMID: 41609404

<https://doi.org/10.1111/hepr.70128>

C 型肝炎患者の初回 DAA 治療失敗後の再治療戦略

2026-02-76

Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan

Ohara M, Kozuka R, Uchida Y, Iino C, Sasaki R, Tojima H, Kawata K, Kakizaki S, Tokumoto Y, Endo M, Asai A, Inoue J, Nagata K, Takahashi H, Shimakami T, Ogawa K, Enomoto M, Ikegami T, Ide T, Sakamoto N, Korenaga M

J Gastroenterol 026-02345-0, Jan 27 [Epub ahead of print] PMID: 41591519

<https://doi.org/10.1007/s00535-026-02345-0>

DAA 治療後 SVR 達成者における長期経過観察の重要性: 日本全国多施設コホート

2026-02-77

Mitochondrial and lipid metabolism rewiring during HEV infection

Glaziou Q, Chen Q, Gouilly J, Wu M, Duhamel M, Salzet M, Izopet J, Al Daccak R, El Costa H, Jabrane-Ferrat N

Cell Mol Life Sci 83(1):56, 2026

PMID: 41507423

<https://doi.org/10.1007/s00018-025-05994-1>

HEV 感染が引き起こすミトコンドリア・脂質代謝異常のメカニズム

2026-02-78

Cost-effectiveness analysis of hepatitis E screening and vaccination: targeting vulnerable populations in outbreak and sporadic settings in China

Liu H, Chen G, Jie Y, Jiang Y, Huang Y, Wang X, Hao C, Gu J, Zhang L, Li J

Emerg Microbes Infect 15(1):2623707, 2026

PMID: 41591925

<https://doi.org/10.1080/22221751.2026.2623707>

中国における E 型肝炎スクリーニングとワクチン接種の費用対効果: ハイリスク層をどう守るか

2026-02-79

Epstein-Barr virus and hepatitis E virus in an immunocompetent adult: A rare case report

Attieh P, Al Hazzouri A, Karam K, El Hajj I, Fiani E

Clin Case Rep 14(2): e71976, 2026

PMID: 41626093

<https://doi.org/10.1002/ccr3.71976>

免疫正常成人に発症した EBV と HEV の重複感染: 稀な症例報告

2026-02-80

Identification of G-quadruplexes in hepatitis E virus negative-sense genomic RNA as potent antiviral targets

Ding X, Zeng D, Bian Y, Liu D, Li Q, Si R, Sha Y, Fu H, Li Y, Ding X, Liu X, Li N, Liang S, Ding Y, Wang W, Guo H

ACS Infect Dis 12(2):854–68, 2026

PMID:41603759

HEV マイナス鎖 RNA に存在する G-quadruplex 同定: 有力な治療標的としての可能性

2026-02-81

Hepatitis E virus infection in patients with chronic liver diseases: A Latin American multicenter study

Fantilli A C, Pisano M B, Martinez Wassaf M, Di Cola G, Balderramo D, Romagnoli P, Prieto J, Arrese M, Carrera E, Diaz Ferrer J, Mattos A Z, Fernandez M, Britos G M, Bernaschini M E, Sepulveda S A, Roa J C, Grutadauria S, Zerega A, Ferreiro M, Gonzalez Ballerga E, Salmon J, Boonstra A, Debes J D, Re V E

J Infect Dis jiaf615, Jan 28 [Epub ahead of print]

PMID: 41603425

<https://doi.org/10.1093/infdis/jiaf615>

慢性肝疾患患者における HEV 感染の実態: ラテンアメリカ多施設研究

2026-02-82

Hepatitis C virus elimination: So close, so far?

Pawlotsky J M

Antiviral Res 247:106360, 2026

PMID:41644064

C型肝炎制圧は目前か、それとも道半ばか？

2026-02-83

Early treatment initiation optimizes virologic and liver outcomes in pediatric patients with chronic hepatitis B aged 0-18 years

Chen L, Jiang L, Zhao B, Jiang Y, Liu S, Li M, Li Y, Jiang Y, Li M, Wei H, Bao C, Niu J, Zhao J

Clin Gastroenterol Hepatol 2026.01.026,

Feb 2 [Epub ahead of print]

PMID:41638417

小児 CHB における早期治療の有益性:ウイルス抑制と肝機能改善が向上

2026-02-84

Peginterferon α -2b enhances HBsAg loss in NA-suppressed low-HBsAg chronic hepatitis B patients: Everest study in China

Xie C, Lin B, Mo Z, Fu L, Chen X, Yang J, Li G, Li J, Zeng Y, Gong G, Zhang W, Tang H, Guo Y, Wei J, Jiang J, Wu X, Lv R, Lin M, Yu Z, Shang J, Guan Y, Li J, Zhang L, Guo Q, Ye Q, Mao Q, Li Y, Xue X, Geng J, Mao X, Lian J, Lu X, Hu G, Bai H, Cai D, Liu Y, Zhang L, Mao Q, Li J, Chen H, Chang J, Li Q, Xie D, Deng H, Xu Q, Peng L, Yang X, Zhuang H, Gao Z

Clin Gastroenterol Hepatol 2026.01.029,

Feb 2 [Epub ahead of print]

PMID: 41638418

<https://doi.org/10.1016/j.cgh.2026.01.029>

NA 治療中の低 HBsAg 例で PEF-IFN 併用が HBsAg 消失を促進:中国 Everest 研究

2026-02-85

A novel systemic inflammation-based model for predicting mortality in HBV-related ACLF

Peng W, Yuan J, Peng S, Fu L

J Med Virol 98(2): e70799, 2026

PMID:41578917

HBV 関連 ACLF の予後を予測する新たな全身炎症ベースのモデル

2026-02-86

Tenofovir alafenamide fumarate reduces virological replication in HBeAg-negative patients with normal alanine aminotransferase: A 48-week randomised controlled trial

Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L
J Viral Hepat 33(3): e70141, 2026

PMID: 41608776

<https://doi.org/10.1111/jvh.70141>

ALT 正常・HBeAg 陰性の CHB 患者で TAF がウイルス抑制に有効:48 週試験

2026-02-87

Trends of advanced chronic liver disease among 17,711 persons in Mongolia during years 2015-2023

Kamal H, Jargalsaikhan G, Enkhtaivan S, Bruce D, Lindahl K, Dashtseren B, Ulziibadrakh T, Batkhuu M, Bat-Ulzii P, Byambabaatar S, Aleman S, Dashdorj N B

J Viral Hepat 33(2): e70129, 2026

PMID: 41492829

<https://doi.org/10.1111/jvh.70129>

モンゴル 17,711 例における進行慢性肝疾患の推移(2015~2023 年)

2026-02-88

Progress towards elimination: Hepatitis B and C among children and young adults in rural Mongolia

Dashdorj E D, Sereenendorj K, Ochirsum B, Bat-Ulzii P, Renchindorj B, Dashdorj A N, Budeebazar M, Enkhbat M, Ochirbat E, Lkhagva-Ochir O, Enkhbat A, Bat S, Yagaanbuyant D, Terrault N, Onom N D D, Bungert A S, Dashdorj N B

J Viral Hepat 33(3): e70145, 2026

PMID:41623214

モンゴル農村部における B 型・C 型肝炎の若年層での減少状況: 排除に向けた進捗

2026-02-89

TNF- α inhibitors and HBV reactivation risk in HBsAg-/anti-HBc+ patients: A systematic review and meta-analysis

Kuo M H, Ko P H, Lee C C, Tseng C W

Liver Int 46(3): e70532, 2026

PMID:41623121

HBsAg 陰性・HBc 抗体陽性例での TNF- α 阻害薬使用と HBV 再活性化リスク: メタ分析

2026-02-90

RAB25 promotes hepatitis B virus-induced liver fibrosis progression through activation of the PI3K/AKT signaling pathway

Liu J, Liu B, Xie X, Yang X, Liu Q

Virus Res 365:199698, 2026

PMID:41651076

RAB25 は PI3K/AKT 経路を介して HBV 関連肝線維化を促進する

2026-02-91

HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients

Xie Y, Zhang X, Yang X, Zheng S, Zhang S, Zhang X, Kang H, Duan X, Cai W, Yin P, Ma X, Liu J, Lu F, Dai L, Feng B

BMC Gastroenterol 26:76, 2026

PMID: 41484832

<https://doi.org/10.1186/s12876-025-04579-3>

NA 治療後 6 ヶ月の HBV RNA 値で治療効果を予測